DelveInsight’s “Choroideremia Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the Choroideremia, historical and forecasted epidemiology as well as the Choroideremia market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.
Choroideremia Key Highlights
Key Companies working in the Choroideremia market include Jazz Pharmaceuticals, Otsuka Pharmaceuticals, Bionomics Limited and many others
Key Therapies included in the Choroideremia market include Brexpiprazole, BNC201, and many others
Choroideremia Overview
Choroideremia is a rare, X-linked recessive form of hereditary retinal degeneration that affects roughly 1 in 50,000 males. The disease causes a gradual loss of vision, starting with childhood night blindness, followed by peripheral vision loss and progressing to loss of central vision later in life. Progression continues throughout the individual’s life, but both the rate of change and the degree of visual loss are variable among those affected, even within the same family.
Choroideremia is caused by a loss-of-function mutation in the CHM gene which encodes Rab escort protein 1 (REP1), a protein involved in the lipid modification of Rab proteins. While the complete mechanism of disease is not fully understood, the lack of a functional protein in the retina results in cell death and the gradual deterioration of the retinal pigment epithelium (RPE), photoreceptors, and the choroid.
Choroideremia Epidemiology Insights
Choroideremia is a rare chorioretinal dystrophy that is estimated to affect between 1 in 50,000 to 1 in 100,000 individuals.
Click here to learn more about the Choroideremia Market Landscape
The Report Covers the Choroideremia Epidemiology Segmented by:
Choroideremia prevalent cases
Choroideremia incident cases
Choroideremia treatment cases
Choroideremia diagnosed cases
Choroideremia Market Outlook
The Choroideremia market outlook of the report helps to build a detailed comprehension of the historic, current, and forecasted Choroideremia market trends by analyzing the impact of current Choroideremia therapies on the market, unmet needs, drivers and barriers, and demand for better technology. This segment gives a thorough detail of the Choroideremia market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Choroideremia market data are presented with relevant tables and graphs to give a clear view of the market at first sight. According to DelveInsight, the Choroideremia market in 7MM is expected to witness a major change in the study period 2019-2032.
Key Companies Working in the Choroideremia Market
Jazz Pharmaceuticals
Otsuka Pharmaceuticals
Bionomics Limited
And many others
Choroideremia Therapies Covered and Analyzed in the Report
Brexpiprazole
BNC201
Learn more about the Key Companies and Emerging Therapies in the Choroideremia Market
Table of Contents
Key Insights
Choroideremia Introduction
Executive Summary of Choroideremia
Disease Background and Overview
Epidemiology and patient population
Choroideremia Emerging Therapies
Market Access and Reimbursement of Therapies
Market Drivers
Market Barriers
Appendix
Report Methodology
DelveInsight Capabilities
Disclaimer
Learn about the detailed offerings of the report @ Choroideremia Market Outlook
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Adya KaulEmail: Send EmailPhone: 919650213330Address:304 S. Jones Blvd #2432 City: Las VegasState: NevadaCountry: United StatesWebsite: https://www.delveinsight.com/consulting/due-diligence-services
